The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 199-204

  Litman, Robert E ^a,b   Smith, Mark A ^c   Desai, Dhaval G ^c   Simpson, Thomas ^c   Sweitzer, Dennis ^c   Kanes, Stephen J ^c  

^a CBH Health   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Monotherapy; Neurokinin 3; Randomized controlled trial; Schizophrenia

Indexed keywords

AZD 2624; NEUROKININ 3 RECEPTOR ANTAGONIST; OLANZAPINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOMNOLENCE; SYMPTOM; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, NEUROKININ-3; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULFONAMIDES; YOUNG ADULT;

EID: 84896394727     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000071     Document Type: Article

References (19)

1. Miyamoto S, Duncan GE, Marx CE, et al. Treatment for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10: 79-104.
2. Meltzer H, Prus A. NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov Today Ther Strateg. 2006;3(4): 555-560.
3. Spooren W, Reimer C, Meltzer H. NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Dis. 2005;4: 967-975.
4. Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Dis. 2012;11(6): 462-478.
5. Dawson LA, Cato KJ, Scott C, et al. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (Talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology. 2008;33: 1642-1652.
6. Dawson LA, Langmead CJ, Dada A, et al. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: improvement in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. Eur J Pharm. 2010;627 (1-3): 106-114.
7. de la Flor R, Dawson LA. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). Neuropharmacology. 2009;56: 342-349.
8. Meltzer HY, Arvinitis L, Bauer D, et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161(6): 975-984.
9. Li Y, Zhou D, Ferguson SS, et al. In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450 enzyme identification, inhibition, and induction studies. Xenobiotica. 2010;40(11): 721-729.
10. Otsuka T, Ito H, Halldin C, et al. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain. J Nucl Med. 2009;50(5): 703-710.
11. Malherbe P, Ballard TM, Ratni H. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005-2010). Expert Opin Ther Pat. 2011;21(5): 637-655.
12. Koback KA, Skodol AE, Bender DS. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I). In: Rush AJ, First MB, Blacker D, eds. Handbook of Psychiatric Measures. 2nd ed. Washington, DC: American Psychiatric Publishing; 2008.
13. Kay SR, Fiszbeina A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987;13: 261-276.
14. Patil ST, Zhang L, Marteny F, et al. Activation of m-GLU 2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med. 2007;13(9): 1102-1107.
15. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976.
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl): 11-19.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychaitry. 1989;154: 672-676.
18. Pharmacology Research Branch, NIMH, Abnormal Involuntary Movements Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised: US Department of Health, Education and Welfare Publication (ADM)76-338. Rockville, MD: NIMH; 1976;534-537.
19. Pietrzak RH, Olver J, Norman T, et al. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009;31: 848-859.